英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
22094查看　22094　在百度字典中的解释百度英翻中〔查看〕
22094查看　22094　在Google字典中的解释Google英翻中〔查看〕
22094查看　22094　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Targeting ALK Rearrangements in NSCLC: Current State of the Art
    Currently, six ALK-target agents have been approved to treat advanced ALK+ NSCLC, including crizotinib, alectinib, ceritinib, ensartinib, brigatinib, and lorlatinib These targeted agents induce durable responses and improve survival outcomes Treatment with ALK inhibitors is recognized as the standard of care for advanced ALK+ NSCLC
  • Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
    Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
  • ALK+ NSCLC Treatment Guidelines
    Use of ALK TKIs is effective for treatment of patients with ALK+ NSCLC and CNS involvement, and evidence supports alectinib, brigatinib or ceritinib in this setting as first-line therapy
  • Neladalkib Demonstrates Promising Responses in ALK+ NSCLC
    Neladalkib shows promising efficacy in advanced ALK+ NSCLC, offering durable responses and manageable safety, potentially transforming treatment options
  • Neladalkib Shows Durable Responses in Heavily Pretreated ALK . . .
    Key Takeaways Neladalkib shows a 31% ORR in advanced ALK-positive NSCLC, with durable responses in 64% and 53% at 12 and 18 months, respectively The drug effectively penetrates the blood-brain barrier, showing significant intracranial activity, especially in lorlatinib-naïve patients and those with the ALK G1202R mutation
  • FDA Approves Alectinib for ALK-Positive Lung Cancer
    Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
  • FDA approves alectinib as adjuvant treatment for ALK-positive . . .
    On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc ) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK
  • ALK Alterations and Treatment Options for ALK+ NSCLC
    Panelists review the discovery of ALK gene fusions and how they have reshaped the treatment landscape for a distinct subset of lung cancer patients They describe how these rearrangements activate
  • Real-world treatment sequencing and effectiveness of second . . .
    With multiple targeted therapies approved for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), it is increasingly important to understand outcomes with various sequences of next-generation ALK tyrosine kinase inhibitors (TKIs) We describe contemporary sequencing patterns and treatment effectiveness of first-line (1L) and second-line (2L) treatments in
  • Real-World Treatment and Outcomes in ALK-Rearranged NSCLC . . .
    ALK–rearranged advanced NSCLC (aNSCLC) represents 4% of all NSCLCs, and multiple ALK-targeted therapies (ALK-inhibitors) are now available for use Little is known about changes in treatment patterns, or how prognostic factors and sequence of therapy may impact overall survival in the real-world setting We aim to describe initial and subsequent treatments used, survival outcomes, prognostic





中文字典-英文字典  2005-2009